Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

VISTA Regulates The Development Of Protective Antitumor Immunity.

I. Le Mercier, Wenna Chen, J. L. Lines, Maria L. Day, Jiannan Li, P. Sergent, R. Noelle, L. Wang
Published 2014 · Biology, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
V-domain Ig suppressor of T-cell activation (VISTA) is a novel negative checkpoint ligand that is homologous to PD-L1 and suppresses T-cell activation. This study demonstrates the multiple mechanisms whereby VISTA relieves negative regulation by hematopoietic cells and enhances protective antitumor immunity. VISTA is highly expressed on myeloid cells and Foxp3(+)CD4(+) regulatory cells, but not on tumor cells within the tumor microenvironment (TME). VISTA monoclonal antibody (mAb) treatment increased the number of tumor-specific T cells in the periphery and enhanced the infiltration, proliferation, and effector function of tumor-reactive T cells within the TME. VISTA blockade altered the suppressive feature of the TME by decreasing the presence of monocytic myeloid-derived suppressor cells and increasing the presence of activated dendritic cells within the tumor microenvironment. In addition, VISTA blockade impaired the suppressive function and reduced the emergence of tumor-specific Foxp3(+)CD4(+) regulatory T cells. Consequently, VISTA mAb administration as a monotherapy significantly suppressed the growth of both transplantable and inducible melanoma. Initial studies explored a combinatorial regimen using VISTA blockade and a peptide-based cancer vaccine with TLR agonists as adjuvants. VISTA blockade synergized with the vaccine to effectively impair the growth of established tumors. Our study therefore establishes a foundation for designing VISTA-targeted approaches either as a monotherapy or in combination with additional immune-targeted strategies for cancer immunotherapy.
This paper references
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
Loise M. Francisco (2009)
Tumor-specific Th17-polarized cells eradicate large established melanoma.
P. Muranski (2008)
BRafV600E cooperates with Pten silencing to elicit metastatic melanoma
D. Dankort (2009)
Interferon γ limits the effectiveness of melanoma peptide vaccines.
Hyun-Il Cho (2011)
Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation
G. Freeman (2000)
Combined TLR and CD40 Triggering Induces Potent CD8+ T Cell Expansion with Variable Dependence on Type I IFN
C. Ahonen (2004)
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
Yoshiko Iwai (2002)
TLR ligand-peptide conjugate vaccines: toward clinical application.
Gijs G. Zom (2012)
Immune system targeting by biodegradable nanoparticles for cancer vaccines.
J. M. Silva (2013)
A Modified Tyrosinase-Related Protein 2 Epitope Generates High-Affinity Tumor-Specific T Cells but Does Not Mediate Therapeutic Efficacy in an Intradermal Tumor Model1
J. A. McWilliams (2006)
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
J. Brahmer (2012)
Amolecular perspective ofCTLA4 function
KirchhofMG TeftWA (2006)
Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+ regulatory T cells
L. Wang (2008)
Particulate formulations for the delivery of poly(I:C) as vaccine adjuvant.
A. Hafner (2013)
CD4+ CD25+ CD62+ T‐Regulatory Cell Subset Has Optimal Suppressive and Proliferative Potential
Shuang Fu (2004)
Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy
Christian Blank (2004)
Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
E. Davila (2003)
Clinical studies with anti-CTLA-4 antibodies in non-melanoma indications.
L. Calabrò (2010)
Regulatory T cell lineage speci fi cation by the forkhead transcription factor foxp 3
JD Fontenot (2005)
Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity.
Fumiya Hirano (2005)
The B7 family revisited.
R. Greenwald (2005)
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
M. Curran (2010)
Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity
T. Curiel (2003)
Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo.
L. Sánchez-Pérez (2005)
Cancer immunotherapy comes of age.
S. Topalian (2011)
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
S. Topalian (2012)
Immunotherapy earns its spot in the ranks of cancer therapy
D. Pardoll (2012)
Braf(V600E) cooperates with Pten loss to induce metastatic melanoma
D Dankort (2009)
Amolecular perspective ofCTLA4 function
KirchhofMG TeftWA (2006)
Cancer-related inflammation
A. Mantovani (2008)
Mast cells impair the development of protective anti-tumor immunity
A. Wasiuk (2012)
PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells
Christian Blank (2004)
Nivolumab plus ipilimumab in advanced melanoma.
J. Wolchok (2013)
Blockade of Programmed Death Ligand 1 Enhances the Therapeutic Efficacy of Combination Immunotherapy against Melanoma
S. Pilon-Thomas (2010)
Myeloid-derived suppressor cells as regulators of the immune system
D. Gabrilovich (2009)
A molecular perspective of CTLA-4 function.
W. Teft (2006)
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses.
M. Butte (2007)
VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses
L. Wang (2011)
Optimized peptide vaccines eliciting extensive CD8 T-cell responses with therapeutic antitumor effects.
Hyun-Il Cho (2009)
The blockade of immune checkpoints in cancer immunotherapy
D. Pardoll (2012)
Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation
A. van Elsas (1999)
grammed death1 ligand 1 interacts speci fi cally with the b 7 – 1 costimulatory molecule to inhibit T cell responses
MJ Butte (2007)
Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccines.
C. Ahonen (2008)
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.
J. Brahmer (2010)
HSP70 vaccine in combination with gene therapy with plasmid DNA encoding sPD‐1 overcomes immune resistance and suppresses the progression of pulmonary metastatic melanoma
Hui Geng (2006)
Anti–Programmed Death-1 Synergizes with Granulocyte Macrophage Colony-Stimulating Factor–Secreting Tumor Cell Immunotherapy Providing Therapeutic Benefit to Mice with Established Tumors
B. Li (2009)
Tumor vaccines expressing flt3 ligand synergize with ctla-4 blockade to reject preimplanted tumors.
M. Curran (2009)
Ipilimumab: attenuation of an inhibitory immune checkpoint improves survival in metastatic melanoma
K. Peggs (2010)
Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies
Yannick Bulliard (2013)
VISTA is an immune checkpoint molecule for human T cells.
J. L. Lines (2014)
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma
Tyler R. Simpson (2013)
Blockade of programmed death ligand 1 enhances the therapeutic efficacy of Anti-VISTA Cancer Immunotherapy April 1, 2014 combination immunotherapy against melanoma
S Pilon-Thomas (2010)
Blockade of programmed death ligand 1 enhances the therapeutic efficacy of Anti-VISTA Cancer Immunotherapy Cancer Res
S Pilon-Thomas (2014)
Coordinated regulation of myeloid cells by tumours
D. Gabrilovich (2012)
Two functional subsets of FOXP3+ regulatory T cells in human thymus and periphery.
T. Ito (2008)
Inhibitory B7-family molecules in the tumour microenvironment
W. Zou (2008)
Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.
A. Hoos (2010)
Blockade of programmed death ligand 1 enhances the therapeutic efficacy of Anti-VISTA Cancer Immunotherapy Cancer Res
S Pilon-Thomas (2014)
Regulatory T cell lineage specification by the forkhead transcription factor foxp3.
J. Fontenot (2005)

This paper is referenced by
Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression.
R. Saleh (2019)
Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma.
Yuta Kondo (2016)
Advances of Immune Checkpoint Inhibitors in Tumor Immunotherapy
Qiao Guo (2018)
Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses
J. Liu (2015)
Immune checkpoint blockade and its combination therapy with small-molecule inhibitors for cancer treatment.
Manni Wang (2019)
Novel Checkpoints and Cosignaling Molecules in Cancer Immunotherapy
I. Giuroiu (2017)
Prevalence and Cellular Distribution of Novel Immune Checkpoint Targets Across Longitudinal Specimens in Treatment-naïve Melanoma Patients: Implications for Clinical Trials
J. Edwards (2019)
Current Challenges in Cancer Immunotherapy: Multimodal Approaches to Improve Efficacy and Patient Response Rates
Manpreet Sambi (2019)
Engineered Materials for Cancer Immunotherapy.
Alexander S Cheung (2015)
Regulation of Cancer Immune Checkpoints: Molecular and Cellular Mechanisms and Therapy
J. Xu (2020)
FoxP3+ T regulatory cells in cancer: Prognostic biomarkers and therapeutic targets.
R. Saleh (2020)
Melanoma: oncogenic drivers and the immune system.
N. Karachaliou (2015)
Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups
L. Andrews (2019)
Next generation immune-checkpoints for cancer therapy.
Chiara Donini (2018)
Harnessing the Complete Repertoire of Conventional Dendritic Cell Functions for Cancer Immunotherapy
Lukas Amon (2020)
Perspectives on the Role of T Cell Negative Immune Checkpoint Receptors in Health and Disease
Tsuyoshi Fujita (2020)
Expression of V-domain immunoglobulin suppressor of T cell activation is associated with the advanced stage and presence of lymph node metastasis in ovarian cancer
H. Liao (2018)
Latest Advances in Targeting the Tumor Microenvironment for Tumor Suppression
Chloé Laplagne (2019)
Recent developments and future challenges in immune checkpoint inhibitory cancer treatment
Bas D Koster (2015)
The CD28-B7 Family in Anti-Tumor Immunity: Emerging Concepts in Cancer Immunotherapy
J. Leung (2014)
Immunotherapy in extensive small cell lung cancer
V. Verma (2019)
Beyond CTLA-4 and PD-1, the Generation Z of Negative Checkpoint Regulators
I. Le Mercier (2015)
Discovery of New Immune Checkpoints: Family Grows Up.
X. Kong (2020)
Expression of V-set immunoregulatory receptor in malignant mesothelioma
Y. S. Chung (2019)
Selective Involvement of the Checkpoint Regulator VISTA in Suppression of B-Cell, but Not T-Cell, Responsiveness by Monocytic Myeloid-Derived Suppressor Cells from Mice Infected with an Immunodeficiency-Causing Retrovirus
K. Green (2015)
Immune checkpoints in tumor microenvironment and their relevance to the development of cancer stem cells.
N. Khosravi (2020)
LAG-3, TIM-3 and VISTA Expression on Tumor-Infiltrating Lymphocytes in Oropharyngeal Squamous Cell Carcinoma—Potential Biomarkers for Targeted Therapy Concepts
N. Wuerdemann (2020)
Immune checkpoint pathways in the ageing immune system and their relation to vasculitides
R. H. Cadena (2020)
VISTA expression on tumor-infiltrating inflammatory cells in primary cutaneous melanoma correlates with poor disease-specific survival
Lawrence F. Kuklinski (2018)
Potential value of V-domain Ig suppressor of T-cell activation for assessing progn osis in cervical cancer and as a target for therapy.
Ledi Kuang (2020)
Immunosuppressive cells in tumor immune escape and metastasis
Y. Liu (2015)
Emerging targets in cancer immunotherapy.
S. Burugu (2018)
See more
Semantic Scholar Logo Some data provided by SemanticScholar